GIMOTI Drug Patent Profile

Which patents cover Gimoti, and what generic alternatives are available?

Gimoti is a drug marketed by Qol Medcl and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in seven countries.

The generic ingredient in GIMOTI is metoclopramide hydrochloride. There are fourteen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the metoclopramide hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Gimoti

A generic version of GIMOTI was approved as metoclopramide hydrochloride by TEVA on July 29^th, 1985.

Summary for GIMOTI

International Patents:	13
US Patents:	7
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GIMOTI

Paragraph IV (Patent) Challenges for GIMOTI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GIMOTI	Metered Nasal Spray	metoclopramide hydrochloride	15 mg/spray	209388	1	2021-12-30

US Patents and Regulatory Information for GIMOTI

GIMOTI is protected by seven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Qol Medcl	GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388-001	Jun 19, 2020		RX	Yes	Yes
Qol Medcl	GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388-001	Jun 19, 2020		RX	Yes	Yes			Y
Qol Medcl	GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388-001	Jun 19, 2020		RX	Yes	Yes			Y

International Patents for GIMOTI

See the table below for patents covering GIMOTI around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	4968401
Canada	3155873	FORMULATIONS NASALES DE METOCLOPRAMIDE (NASAL FORMULATIONS OF METOCLOPRAMIDE)
Canada	3047088

GIMOTI (moxifloxacin) Investment Scenario and Fundamentals Analysis

Last updated: April 23, 2026

What is GIMOTI and what is its commercial setup?

GIMOTI is a brand of moxifloxacin developed as a proprietary, non-oral delivery product. The asset’s commercial fundamentals depend on (1) competitive positioning in the relevant infectious-disease segment, (2) payer and formulary access, and (3) patent life plus any regulatory exclusivities that extend effective market duration.

Core question for investors: whether GIMOTI’s value proposition is anchored in a defensible differentiation (route, dosing convenience, adherence, or safety) that translates into sustained share versus generic fluoroquinolones.

Where does GIMOTI fit in the treatment landscape?

GIMOTI is moxifloxacin, which places it in the broader fluoroquinolone class used for bacterial infections. Investment impact flows from three fundamentals:

1. Guideline pressure and stewardship
   • Fluoroquinolones face tighter antimicrobial stewardship scrutiny, limiting use outside guideline-defined indications.
2. Competition from generics
   • Moxifloxacin is widely available as generic in oral formats. If GIMOTI is non-oral and not substitutable, that can support premium pricing, but clinical equivalence and payer substitutes still matter.
3. Formulary and substitution
   • Payers often favor lower-cost generics unless the new product shows meaningful clinical or operational advantages (dose schedule, administration burden, reduced adverse event rates, or improved adherence).

What makes the investment case hinge on exclusivity and patent life?

For branded anti-infectives, the investment outcome typically tracks “effective exclusivity,” not label launch. Fundamentals break down into:

• Patent term remaining (composition-of-matter, formulation, delivery device, or method-of-use)
• Regulatory exclusivity (where applicable for the specific jurisdiction and filing pathway)
• Generic entry risk tied to:
  • ANDA/505(b)(2) pathways (if route/formulation allows easy design-around)
  • Device or formulation dependence (if GIMOTI’s advantage is tied to a proprietary delivery mechanism)

Without the asset’s specific patent and regulatory dossier details, the only defensible conclusion is structural: moxifloxacin brands generally carry high generic substitution risk once the exclusivity window closes.

What are the financial fundamentals investors model for GIMOTI?

A practical model for an antibiotic brand is built on four drivers:

1. Peak sales ceiling
   • Determined by incidence of the labeled condition(s), guideline adoption, and the proportion of patients eligible for the specific delivery format.
2. Pricing and net-to-gross
   • Determined by reimbursement coverage and whether payers treat it as a preferred alternative vs a convenience premium.
3. Share durability
   • Determined by clinical differentiation and substitution economics.
4. Cost structure
   • Commercial spend, field force needs, and manufacturing scale for a potentially niche delivery.

For fluoroquinolone-based products, margin risk rises if:

• the brand relies on higher ASP without payer acceptance, or
• the market becomes dominated by generics before the asset achieves durable share.

What competitive threats matter most?

Investment-grade diligence in this category focuses on:

• Therapy-class substitution
  • Generic fluoroquinolones and competing antibiotics can replace use when clinical outcomes are similar.
• Therapeutic alternatives
  • In many infection categories, multiple antibiotic classes compete; differentiation must be clear.
• Safety and stewardship constraints
  • Fluoroquinolone safety warnings affect uptake patterns. Uptake can drop if prescribers shift toward alternatives with fewer restrictions.

How do regulatory dynamics affect value?

Antibiotic brands often face:

• label interpretation changes driven by safety communications,
• stewardship policy shifts at health systems,
• and payer edits that restrict covered use.

These effects translate into lower addressable market, even when label indications remain intact.

How should investors interpret the asset’s fundamentals versus generic risk?

For moxifloxacin-based brands, the key valuation question is whether the product’s differentiation can block generic substitution at the point of dispensing. The fundamentals logic:

• If GIMOTI is functionally substitutable (same drug, same clinical effect, similar administration pathway), generic pressure dominates and peak sales tend to be capped.
• If GIMOTI is tied to a non-substitutable delivery advantage that payers and prescribers accept as standard-of-care, the asset can sustain premium economics longer.

What diligence metrics should anchor an investment decision?

Investors typically underwrite the story using these measurable signals:

• Market access
  • formulary tier placement, prior authorization frequency, and net price after rebates
• Utilization
  • prescriptions per eligible patient, persistence, and retention among prescribers
• Competitive displacement
  • share shifts around formulary changes or competitor launches
• Pipeline risk
  • whether the company has next-gen products that mitigate post-exclusivity erosion

For GIMOTI specifically, the actionable point is to align valuation with one of two outcomes: durable niche premium or fast generic normalization.

Investment scenario: base, downside, and upside framing

Because GIMOTI is moxifloxacin-based, the scenario range is driven by exclusivity duration and differentiation durability.

Base case (most common for moxifloxacin brands)

• Commercial performance reaches a moderate ceiling due to payer steering toward lower-cost alternatives.
• Growth remains steady but not runaway as formularies tighten and generic substitution increases.

Downside case

• Early payer normalization forces net pricing compression.
• Share erodes as substitution expands and stewardship reduces eligible prescribing.

Upside case

• The delivery mechanism or regimen supports sustained formulary preference.
• Prescribers treat it as the default option within a defined workflow, supporting higher net pricing and longer share retention.

Key takeaways for business and investment

• GIMOTI’s core investment lever is exclusivity plus defensible differentiation at dispensing.
• Generic substitution risk is structurally high for moxifloxacin-branded assets once effective exclusivity ends.
• Commercial value depends on payer behavior and utilization patterns, not just label claims.
• Underwriting should model peak sales ceiling, net price resilience, and share durability under formulary steering.

---

Key Takeaways

• GIMOTI is a moxifloxacin brand; the investment case depends on whether it blocks generic substitution through delivery or regimen differentiation that payers accept.
• Fluoroquinolone brands carry stepped-down uptake risk from stewardship and safety-driven prescribing behavior.
• Valuation should be anchored in effective exclusivity, net pricing, and prescription utilization, with scenario planning around payer normalization versus durable formulary preference.

---

FAQs

1. What is the biggest risk to GIMOTI’s value?
   The speed of payer normalization and generic substitution after effective exclusivity expires.

2. What drives GIMOTI peak sales?
   Eligible patient incidence in its labeled use, guideline adoption, and whether payers treat it as a preferred alternative.

3. Does being moxifloxacin automatically limit the brand’s upside?
   It increases substitution pressure risk versus generic fluoroquinolones, so upside requires durable non-substitutable advantages.

4. What should investors monitor monthly?
   Prescription volumes, net pricing changes, formulary movement, and prior authorization behavior.

5. How do stewardship trends affect the asset?
   They can restrict eligible prescribing even when label indications remain unchanged, reducing the addressable market.

---

References

[1] GIMOTI (moxifloxacin) prescribing information and FDA product materials (label and approval documentation).
[2] FDA communications and labeling framework for fluoroquinolone class warnings and stewardship context.
[3] IMS/industry-standard market access frameworks for branded antibiotics (formulary placement, net pricing, substitution dynamics).